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Abstract
Options for the control of emerging and reemerging H5N1 influenza viruses include improvements in biosecurity and the use of
inactivated vaccines. Commercially available H5N2 influenza vaccine prevents disease signs and reduces virus load but does not completely
prevent virus shedding after challenge with H5N1 virus. By using reverse genetics, we prepared an H5N3 vaccine whose hemagglutinin is
99.6% homologous to that of A/CK/HK/86.3/02 (H5N1). We used the internal genes of A/PR/8/34 and the H5 of A/Goose/HK/437.4/99
(H5N1) after deletion of basic amino acids from its connecting peptide region. The resulting virus was not lethal to chicken embryos and
grew to high HA titers in eggs, allowing preparation of HA protein-standardized vaccine in unconcentrated allantoic fluid. The N3
neuraminidase, derived from A/Duck/Germany/1215/73 (H2N3), permitted discrimination between vaccinated and naturally infected birds.
The virus construct failed to replicate in quail and chickens. Similar to parental A/PR/8/34 (H1N1), it replicated in mice and ferrets and
spread to the brains of mice; therefore, it should not be used as a live-attenuated vaccine. The H5N3 vaccine, at doses of 1.2 g HA, induced
HI antibodies in chickens and prevented death, signs of disease, and markedly reduced virus shedding after challenge with A/CK/HK/
86.3/02 (H5N1) but did not provide sterilizing immunity. Thus, reverse genetics allows the inexpensive preparation of standardized,
efficacious H5N3 poultry vaccines that may also reduce the reemergence of H5N1 genotypes.
© 2003 Elsevier Inc. All rights reserved.
Keywords: Reverse genetics derived influenza H5N3 vaccines; Chickens; Efficacy; Safety testing
Introduction
The emergence in Hong Kong of H5N1 influenza viruses
that are highly pathogenic in domestic poultry and in hu-
mans provided the first evidence of lethal disease caused by
direct transmission of avian influenza viruses to humans (de
Jong et al., 1997; Claas et al., 1998; Shortridge et al., 1998;
Subbarao et al., 1998; Yuen et al., 1998). The potential
evolution of an H5N1 virus capable of human-to-human
transmission was prevented by the slaughter of all poultry in
Hong Kong in December 1997; afterward, cases of human
H5N1 infection in Hong Kong swiftly disappeared (Sub-
barao and Katz, 2000). In 2001, the reemergence of H5N1
viruses of multiple genotypes (Guan et al., 2002a) was once
more controlled by the slaughter of poultry in Hong Kong;
the removal of virus from poultry markets precluded poten-
tial transmission to humans. The further reemergence of
H5N1 influenza viruses in poultry in Hong Kong in Febru-
ary and November 2002 (J.S. (Malik) Peiris, unpublished
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data) was controlled by the slaughter of H5N1-positive
flocks and infected poultry stalls in markets.
The putative parents of the H5N1/97 virus continue to
circulate in poultry in the region; these comprise A/Goose/
Guangdong/1/96(H5N1)-like virus, which provided the
hemagglutinin (HA) gene, and the counterparts of A/Quail/
Hong Kong/G1/97 (H9N2) and A/Teal/Hong Kong/
W312/97 (H6N1), which provided the seven other gene
segments (Cauthen et al., 2000; Webster et al., 2002b; Guan
et al., 1999; Chin et al., 2002). In view of the opportunities
for reassortment provided by the live poultry markets, it is
not surprising that highly pathogenic H5N1 strains have
continued to emerge. Studies of the multiple genotypes of
the extremely pathogenic H5N1/01 and H5N1/02 viruses
(Guan et al., 2002b) illustrate the propensity of the H5
hemagglutinin gene of A/Goose/Guangdong/1/96 (H5N1)-
like viruses to generate highly pathogenic phenotypes by
acquiring a variety of gene segments that are compatible
with it.
Strategies to attempt to control the emergence of highly
pathogenic H5N1 viruses in Hong Kong poultry markets
have included the following: (1) After emergence of an
H5N1 influenza virus in 1997 all the poultry in Hong Kong
were slaughtered. In 2001, only birds in the markets and
birds due to go to the markets were slaughtered, as no farms
in Hong Kong were shown to be infected (Sims et al.,
2002a,b). In the February–March 2002 outbreaks, slaughter
of poultry was confined to infected farms and live poultry
markets. (2) Serological screening of each truckload of
poultry sold from local farms or entering Hong Kong SAR
(Sims et al., 2003a,b). (3) Removal of aquatic birds includ-
ing ducks and geese from the live poultry markets in 1998
(Sims et al., 2003a,b). (4) Introduction of one “clean day”
per month when all poultry markets are simultaneously
empty and are cleaned (Sims et al., 2003a,b). (5) Quail was
identified as the poultry species that continued to reintro-
duce H6N1 and H9N2 viruses into the Hong Kong poultry
markets and were banned (Sims et al., 2003a,b). While these
measures have been successful at removing the different
H5N1 influenza virus genotypes from Hong Kong poultry
markets, they have so far not prevented reemergence of
H5N1 influenza viruses. After the third reintroduction of
H5N1/02 influenza virus in Hong Kong, the decision was
made to investigate the use of inactivated vaccine to reduce
the H5N1 virus load and inhibit the further reemergence of
H5N1 genotypes. Additional emphasis was also placed on
improving sanitation and biosecurity on farms.
Inactivated vaccine was successfully used to control the
H5N2 outbreak in Mexico in 1995 (Villard and Flores,
1997). We investigated the efficacy of commercially avail-
able H5N2 influenza vaccine against H5N1/02 influenza
viruses from Hong Kong. We also investigated the use of
reverse genetics to prepare an H5N3 vaccine that is inex-
pensive, simple to create, efficacious, and, most impor-
tantly, standardized for antigen content. Each of these goals
was achieved, as described here. This article serves as proof
of the principle that reverse genetics can provide inexpen-
sive, standardized agricultural influenza vaccines.
Results
Efficacy of commercial H5N2 vaccines
The only commercially available inactivated H5 influ-
enza vaccine is against A/CK/Mexico/232/94 (H5N2). The
HA of this virus has an 89.3% amino acid sequence identity
with the HA of A/Chicken/Hong Kong/86.3/02 (H5N1).
Because the H5N2 influenza virus used in the commercial
vaccine was not available to us, we used a virus isolated
during the same outbreak [A/CK/Hidalgo/232/94 (H5N2)]
in serologic studies. To evaluate the immune response after
single and multiple doses of commercial inactivated H5N2
influenza vaccine, we vaccinated 8-day-old chickens with
one or two doses. A single dose of A/CK/Mexico/232/94
(H5N2) vaccine induced higher hemaggtutination inhibition
(HI) titers to A/CK/Hidalgo/232/94 (H5N2) (1:100) than to
A/CK/HK/86.3/02 (H5N1) (1:20) (Table 1) that increased
after challenge. After two doses of vaccine, higher levels of
prechallenge antibodies were induced that did not increase
after virus challenge.
To evaluate the efficacy of commercial H5N2 vaccine
against A/CK/HK/86.3/02 (H5N1), we performed three ex-
periments (Table 1). The first determined the efficacy of a
single dose of vaccine followed by a modest challenge dose
of ten 50% chicken lethal doses (CLD50) of A/CK/HK/
86.3/02 (H5N1). None of the 19 vaccinated chickens devel-
oped disease signs; in contrast, six of the nine unvaccinated
controls developed disease signs and died within 2–3 days.
Although the 19 vaccinated birds showed no disease signs,
6 birds shed low levels of virus in their feces, and 1 of 10
unvaccinated contact birds became infected but did not die.
In the second experiment, the birds received two doses of
vaccine and developed higher levels of HI antibodies (Table
1); these birds were challenged more aggressively with 100
CLD50 of A/CK/HK/86.3/02 (H5N1) (Table 1). Despite
their relatively high levels of HI antibodies (1/333), 1 of the
10 birds died 9 days after challenge, 3 shed virus in the
trachea, and half (3/6) of the contact unvaccinated birds
died. All unvaccinated challenged birds died within 2–3
days. The bird that died had the lowest HI titer to the
challenge virus (1/80).
In a third experiment (Table 1), birds that had received
two doses of vaccine were challenged under conditions
more akin to field conditions by being exposed to dying
birds that had been inoculated with 100 CLD50 of A/CK/
HK/86.3/02 (H5N1). Under these conditions, none of the
vaccinated birds developed disease signs or died, but one
shed virus (from the trachea).
Thus commercial inactivated oil-emulsion A/CK/Mexi-
co/232/94 (H5N2) provides protection against challenge
with low doses of A/CK/HK/86.3/02 (H5N1) virus but did
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not prevent virus shedding, which transmitted to contact
birds. When the severity of challenge was increased in the
second experiment, 1 of 10 vaccinated birds died but not in
the third experiment. However, virus shedding in vaccinates
in the first experiment was sufficient to infect 50% of
unvaccinated contact controls. Despite high levels of HI
antibody, the heavily challenged birds were not fully pro-
tected, thus raising the question of lack of genetic similarity
between the vaccine and challenge virus.
Description of H5N3 vaccine derived by reverse genetics
The commercially available inactivated H5 influenza
vaccines for poultry contain H5N2 virus from 1994 and are
only 89.3% homologous at the amino acid level with
H5N1/02 viruses from Hong Kong. Therefore, we used
reverse genetics to make a high-yield, nonpathogenic H5N3
virus. We used the egg-adapted, high-growth influenza
A/Puerto Rico/8/34 (H1N1) virus (PR8) as the donor of the
internal genes, which had previously been cloned and res-
cued by reverse genetics (Hoffmann et al., 2002). We used
the modified H5 hemagglutinin gene of A/Goose/Hong
Kong/437-4/99 (H5N1) virus. This H5 hemagglutinin gene
is antigenically closely related to the HA gene of A/CK/
HK/86.3/02 (H5N1). To prevent the generation of a highly
pathogenic virus, we deleted the nucleotides encoding four
basic amino acids at the HA1–HA2 cleavage site, creating a
cleavage site resembling that of the nonpathogenic H6 HA
gene of influenza A/Teal/Hong Kong/W312/97 (Fig. 1). The
N3 neuraminidase gene was obtained from the A/Duck/
Germany/1215/73 (H2N3) virus. The N3 gene was chosen
to generate a virus that can be used as a vaccine but that also
allowed us to distinguish vaccinated birds from infected
birds by detection of antibodies to N3.
Table 1
Efficacy of commercially available inactivated H5N2 vaccine (A/Chicken/Mexico/232/94) in chickens
Vaccination status Challenge virus Mean HI antibody titer Dead/total
(dpc)
Virus isolation (no. positive/total) 3 dpc
to CK/HK/86.3/02
(H5N1)
to CK/Hidalgo/232/94
(H5N2)
Prechallenge Postchallenge Prechallenge Postchallenge Trachea (titer) Cloaca (titer)
Experiment 1
Vaccinated, 8 days
old
10 CLD50 A/Ck/HK/
86.3/02 (H5N1)
20  5 53  8 100  15 150  20 0/19 0/19 6/19 ( 1 log10/ml)
Unvaccinated contacts None 0/10 0/10 1/10 ( 1 log10/ml)
Unvaccinated controls 10 CLD50 A/Ck/HK/
86.3/02 (H5N1)
6/9 (2–3) 0/3 1/3
Experiment 2
Vaccinated 8 days old
and boosted 28
days later
100 CLD50 A/Ck/HK/
86.3/02 (H5N1)
333  134 337  80 391  80 257  56 1/10 (9) 3/10 (1–2.25
log10/ml)
0/10
Unvaccinated contacts None 3/6 (4) 3/6 ( 1–2.25
log10/ml)
2/6
Unvaccinated controls 100 CLD50 A/CK/86.3/
02 (H5N1)
9/9 (2–3) ND (Dead) ND (Dead)
Experiment 3
Vaccinated 8 days old
and boosted 28
days later
Exposed to birds
infected with 100 CLD50
A/CK/HK/86.3/02
(H5N1)
282  82 252  72 388  74 326  76 0/10 1/10 0/10
Unvaccinated contacts Exposed to birds
infected with 100 CLD50
A/CK/HK/86.3/02
(H5N1)
3/4 (2) 0/1 (3 Dead) 0/1 (3 Dead)
dpc: days postchallenge; ND: not done.
Fig. 1. Modified A/Goose/HK/437-4/99 (H5N1) hemagglutinin sequence.
Twelve nucleotides in the wild-type cDNA were deleted by genetic engi-
neering to generate a recombinant H5-virus in which the basic amino acids
(Arg Lys Lys Arg) flanking the cleavage site (represented by*) were
deleted.
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Properties of parental and reverse genetics derived
viruses
In vitro properties
The reverse genetics derived H5N3 (rgH5N3) viruses
were characterized by their growth potential and plaque-
forming ability in chicken embryos and in tissue culture
(Table 2). The rgH5N3 virus grew to the same HA titer as
the parental PR8 virus and thus has the desirable property of
producing high yields of HA protein. With its modified HA,
the rgH5N3 virus failed to kill chicken embryos or to
produce plaques in tissue culture in the absence of trypsin,
whereas the parental A/Goose/HK/437-4/99 (H5N1) virus
killed chicken embryos and produced plaques in MDCK
cells in the presence and absence of trypsin. The other
parental viruses [PR8 (H1N1), A/Duck/Germany/1215/73
(H2N3)] and the rgH5N3 virus produced plaques only in the
presence of trypsin. Therefore, the rgH5N3 virus has the
following characteristics of a nonpathogenic virus: the ab-
sence of polybasic amino acids at the connecting peptide
region of the HA, the inability to kill chicken embryos, and
the failure to form plaques in tissue culture without trypsin.
In vivo properties
To determine the pathogenicity of the parental and reas-
sortant viruses, we inoculated chickens, quail, mice, and
ferrets. The rgH5N3 virus did not replicate in quail and
chickens and was nonpathogenic, whereas the A/Gs/HK/
437-4/99 (H5N1) was highly pathogenic in chickens (Table
3, see B). In mice, the rgH5N3 was less pathogenic than the
parental PR8 or rgPR8 viruses. On day 3 after inoculation,
pulmonary virus titers were similarly high in mice inocu-
lated with rgH5N3, the parental PR8, or rgPR8. By day 7,
the parental and rgPR8 viruses had killed the mice, whereas
the rgH5N3 had not, although it was detectable at high titers
in the lungs (6.2 log10 EID50). Both the parental PR8 and the
rgH5N3 viruses were detected in the brains of mice on day
3 or 4 after inoculation, although titers of parental PR8 were
higher. By day 7 postinoculation, the parental virus had
killed all inoculated mice, whereas the rgH5N3 had not, and
no rgH5N3 virus was detected in the brain. The parental
A/Goose/HK/437-4/99 (H5N1) and A/Duck/Germany/
1215/73 (H2N3) viruses showed limited replication in mice
(Table 3 see A).
In ferrets, the rgH5N3 viruses were detected in nasal
washes on days 3 and 5 postinoculation, but at lower titers
than the parental PR8 or rgPR8 viruses. The parental
A/Goose/HK/437-4/99 (H5N1) replicated poorly in ferrets,
whereas the A/Duck/Germany/1215/73 (H2N3) was de-
tected at modest titers in nasal washes for up to 7 days.
Daily measurement of temperature and observation revealed
no disease signs in any of the ferrets; all animals gained
weight and developed antibodies to the inoculated viruses.
Overall, the rgH5N3 virus was completely nonpatho-
genic in chickens and quail, and there was no evidence of
virus replication. In ferrets and mice, the rgH5N3 virus was
less pathogenic than the parental viruses.
Stability of rgH5N3 virus on passage
The rgH5N3 virus was passaged multiple times in
chicken embryos to determine its genetic stability. At each
passage, the eggs were examined for evidence of embryo
death and for HA titer. After 14 passages, the HA gene was
sequenced and the virus was tested antigenically with
postinfection chicken antiserum. There was no evidence
that the virus reverted to virulence in these 14 passages:
there were no dead eggs; the HA sequence remained the
same (Fig. 1); the pathogenicity did not change, and the
virus retained its high growth characteristics (results not
shown).
Yield of hemagglutinin protein from rgH5N3 virus
Although HA titers measure the ability of a virus to
agglutinate erythrocytes, they do not accurately quantify
HA protein content. We used single radial diffusion assays,
which are conventionally used to standardize human influ-
enza vaccine, to estimate the yield of HA protein from the
rgH5N3 reassortant, and to standardize the vaccine for use
in efficacy studies in chickens (Table 2). After inactivation
of virus in allantoic fluid, the HA titer fell by approximately
75%, but the antigen content, as measured by single radial
diffusion, remained constant.
Table 2
Properties of parental and reverse genetics-derived viruses
Virus strain HA titer Infectivity
titer
(EID50)
Embryo death
(CLD50)
H5 protein
(g/ml)
Plaque number in MDCK
 Trypsin  Trypsin
A/PR/8/34 (H1N1) 2048 8.38 No NA 2.1  107 0
A/Goose/HK/437.4/99 (H5N1) 512 8.16 Yes (8.16) NA 3.9  105 2.8  105
A/Duck/Germany/1215/73 (H2N3) 256 9.63 No NA 2.9  106 0
rgH5N3-unmodified 2048 8.50 No 11.8 5.1  106 0
rgH5N3-allantoic fluid vaccine 640 11.8 NA NA
rgH5N3-Amicon vaccine 20,480 75.9 NA NA
rgH5N3-purified vaccine 102,400 5500 NA NA
NA  not applicable.
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Efficacy of the rgH5N3 vaccines
To determine the efficacy of rgH5N3 vaccines against
highly pathogenic A/CK/HK/86.3/02 (H5N1) virus in
chickens, we used three experiments to answer different
questions.
The first experiment investigated whether the H5N3 vac-
cine must be concentrated and purified to yield sufficient
antigen to induce protective immunity against the highly
pathogenic A/CK/HK/86.3/02 (H5N1) strain in chickens.
Groups of five chickens were vaccinated with standardized
doses of allantoic fluid containing rgH5N3 virus, with 10-
fold Amicon-concentrated allantoic fluid containing
rgH5N3 virus, or with concentrated and purified rgH5N3
virus. Each of the H5N3 vaccine preparations induced sim-
ilar high levels of HI antibody to both A/Gs/HK/437-4/99
(H5N1) and A/CK/HK/86.3/02 (H5N1), showing the close
antigenic similarity of these viruses (Table 4). The mean HI
Table 3
Animal testing of rg H5N3 vaccine and parental viruses
Virus Animal Route of
inoculation
Pathogenicitya Dose of
inoculum
(log10 EID50)
Virus titer (log10
EID50) Lung or
nasal wash
Brain SeroConversion
HI Antibody
Titer
D 3/4 D
5
D
7
D 3/4 D 7 D0 D 11/14
A. In mice and ferrets
A/PR/8/34 Mice IN 1.9 6.2 7.0 NA —b 3.3 —b NA NA
Ferrets IN None 7.2 5.3 3.3 d NA NA  40 20,480
A/Goose/HK/437-4/99 Mice IN —f 6.8 3.2 NA 1.5  NA NA NA
Ferrets IN None 5.8 1.4   NA NA  40 80–160
A/Duck/Germany/1215/73 Mice IN 6.9 6.2  NA    NA NA
Ferrets IN None 7.2 3.2e 2.1 1.9e NA NA  40 160
rgH5N3 Mice IN 6.0 5.5 7.7 NA 6.2 1.8  NA NA
Ferrets IN None 6.5 3.2 2.3  NA NA  40 160
rgPR8 Mice IN 3.3 7.3 8.5 NA –b  –b NA NA
Ferrets IN None 7.6 4.5 4.6  NA NA  40 20,480
Virus Animal Route of
inoculation
Dose of inoculum
(log10EID50)
Virus isolation on day
2, 4, or 6 p.i.
Disease signs/dead/total
Trachea Cloacal
B. In quail and chicken
A/Goose/Hong Kong/437-4/99 Chicken IV 6.1 8/8 8/8 8/7/8
rgH5N3 Quail IN, IO, IT 7.2 0/4 0/4 0/0/4
Chicken IN, IO, IT 7.5 0/6 0/6 0/0/6
Chicken IV 6.8 0/8c 0/8 0/0/8
IN, Intranasal; IV, intravenous; IO, intraocular; IT, intratracheal.
a Log10LD50 values are shown as the number of log10EID50 resulting in 50% mortality.
b All mice died.
c Chickens swabbed on day 3 only.
d , no virus detected.
e The average EID50 from two ferrets; no virus was detected in one animal.
f Pathogenicity was determine by inoculation with 106.8 EID50 and resulted in 50% mortality (n  8).
d: day after inoculation; NA: not applicable.
Table 4
H1 responses induced by allantoic-fluid, Amicon-concentrated, and purified rgH5N3 vaccines in chickens (Experiment 1)
Vaccine HA antigen dose (g) HI titer to Ck/HK/86.3/02
(H5N1) before challenge
HI titer to Gs/HK/437-4/99
(H5N1) before challenge
Allantoic fluid oil-emulsion 1.2 194 (10–320) 196 (100–320)
Amicon-concentrated (10) oil-emulsion 7.6 168 (80–640) 184 (80–640)
Amicon-concentrated (10) 1:10 diluted oil-emulsion 0.76 192 (80–320) 192 (80–320)
Purified 1:31.6 diluted oil-emulsion 17.4 169 (80–320) 169 (80–320)
Purified 1:100 diluted oil-emulsion 5.5 256 (160–320) 256 (160–320)
Control 0 0 0
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titer induced by the allantoic fluid vaccine (1:194) was as
high as those induced by the Amicon-concentrated vaccine
(1:168) or purified vaccine (1:192), and higher doses of
purified H5N3 antigens did not induce higher HI titers than
unconcentrated allantoic fluid vaccine.
In the second experiment (Table 5), the same allantoic
fluid, Amicon-concentrated, and purified vaccines were
given to groups of nine chickens. An additional group of
chickens was vaccinated with purified vaccine in Freund’s
incomplete adjuvant to determine the comparative efficacy
of the oil-emulsion vaccine. Three weeks later, one chicken
infected with 100 CLD50 of A/CK/HK/86.3/02 (H5N1) was
introduced into each group of nine vaccinated birds to
mimic field conditions of exposure. None of the groups of
vaccinated chickens (Table 5) developed signs of disease,
and none of the birds died. However, two birds that received
the allantoic fluid vaccine and one that received the Ami-
con-concentrated vaccine shed virus at very low levels (de-
tectable only in undiluted samples). In comparison, all nine
of the control unvaccinated birds developed signs of highly
pathogenic influenza infection, and eight died. It is note-
worthy that the Freund’s adjuvant vaccine did not induce
antibody titers as high as those induced by the oil-emulsion
vaccine mean (HI titer  1:67 for Freund’s vaccine group
versus 1:190 for the oil emulsion group) and both groups
provided complete protection with no virus shedding after
challenge.
The third experiment was conducted to determine the
dose response to the allantoic fluid vaccine and to determine
how often virus shedding was detected in vaccinated birds
(Table 5). The allantoic fluid vaccine containing 1.2 g/
dose of HA protein was very efficacious, with disease signs
or death observed in 0/26 birds; only 1/26 shed virus (very
low levels, detectable only in undiluted samples). When the
allantoic fluid vaccine was diluted 10-fold (0.12 g/dose),
no HI antibodies were detected in prechallenge sera from
vaccinated birds; all birds shed virus, and 6/9 died.
Overall, these results show that the allantoic fluid of the
H5N3 vaccine in oil-emulsion adjuvant is efficacious
against A/CK/HK/86.3/02 (H5N1) influenza virus without
concentration or purification. A single dose of vaccine con-
taining 1.2 g of H5 antigen prevents disease signs and
death and reduces virus shedding to very low titers.
Induction of neuraminidase-inhibiting antibodies
The rgH5N3 vaccine was designed to allow distinction
between birds infected in the field with H5N1 virus and
those vaccinated with H5N3 vaccine. Neuraminidase inhi-
bition (NI) titrations revealed antibodies to N3 in all sera
that contained HI antibodies to H5. Birds vaccinated with
1.2 g of rgH5N3 vaccine had a mean prechallenge titer of
1:67 to N3 and 1:27 to H5.
Discussion
The persistent reemergence of H5N1 influenza viruses in
poultry in southeast China is of continuing concern to med-
ical and veterinary public health officials. Although we
know that the H5N1/97 was transmitted to 18 hospitalized
persons and killed 6, we do not know the capacity of the
H5N1 genotypes isolated from poultry in Hong Kong in
2001 and 2002 to infect humans. Experiments in chickens
and quail show that these viruses are highly pathogenic
(Guan et al., 2002a), and they are neurovirulent in mice
without adaptation (Lipatov et al., 2003). Therefore, the
2001 and 2002 H5N1 viruses may have the potential to
infect humans. The very recent detection of H5N1 virus in
two humans in Hong Kong (February 2003) underscores
these concerns.
Despite multiple strategies used to inhibit the reemer-
gence of H5N1 influenza viruses in Hong Kong poultry
markets (reviewed in the Introduction), nothing has so far
prevented the reemergence of different genotypes of H5N1
viruses. After May 2002, inactivated A/CK/Mexico/232/94
(H5N2) oil emulsion vaccine was used at 22 farms near the
4 farms in the New Territories of Hong Kong that had had
outbreaks in early 2002. No outbreaks of H5N1 infection or
disease has occurred at these 22 farms, despite recent out-
Table 5
Efficacy of allantoic-fluid, Amicon-concentrated, and purified rgH5N3 vaccines against naturally transmitted H5N1/02 virus
Vaccine HA antigen
dose (g)
Dead/
total
Virus shedding/
total on day 4
Mean HI titer to
A/Ck/HK/86.3/02 (H5N1)
pre/postchallenge
Experiment 2
Allantoic fluid oil-emulsion 1.2 0/9 2/9 ND/133 (40–320)
Amicon-concentrated (10) 1:3.16 diluted oil-emulsion 2.4 0/9 1/9 ND/133 (80–330)
Purified, 1:100 diluted oil-emulsion 5.5 0/9 0/9 ND/226 (40–640)
Purified 1:100 Freund’s adjuvant 5.5 0/9 0/9 40/67 (40–160)
Control 8/9 5/6
Experiment 3
Allantoic fluid oil-emulsion vaccine 1.2 0/26 1/26 15.8/110 (0–640)
Allantoic fluid 1:10 diluted oil-emulsion vaccine 0.12 6/9 4/9 0/33.3 (0–80)
PBS control 26/27 22/27 0/(0–20)
585M. Liu et al. / Virology 314 (2003) 580–590
breaks (December 2002–January 2003) in two waterfowl
parks and five local chicken farms, and despite concurrent
lethal H5N1 virus infections in wild ardeid birds (little
egrets and grey herons) and waterbirds (black-headed gulls,
flamingos, geese, swans, and ducks) in Hong Kong. There-
fore, the A/CK/Mexico/232/94 (H5N2) is an efficacious
vaccine against H5N1 viruses under field conditions in
Hong Kong, despite antigenic drift in the hemagglutinin.
Inactivated influenza vaccine to highly pathogenic influ-
enza viruses is a viable option for control strategies
(Swayne et al., 2000). H5N2 influenza outbreaks in domes-
tic poultry in Mexico in 1994 were controlled by improving
sanitation and biosecurity and by using inactivated vaccine
(Villard and Flores, 1997). The use of vaccination without
improved sanitation and biosecurity would be very unsound
and could mask the presence of H5N1 virus. Mexico has
been successful at using the combination of improved bio-
security and vaccination to eradicate highly pathogenic in-
fluenza viruses from poultry.
Our findings show that both commercially available
H5N2 vaccine and reverse genetics prepared H5N3 vaccine
are efficacious at preventing signs of infection by highly
pathogenic H5N1 viruses and at reducing virus shedding
and spread to contact birds. The advantage of the H5N2-
inactivated vaccine is that it is commercially available and
has been used in large numbers of poultry. The disadvantage
is that the commercial H5N2 vaccine is not standardized for
antigen content, which may differ from batch to batch.
H5N2 vaccines produced for use in Mexico were shown to
vary substantially among batches; some batches were effi-
cacious, while others, prepared by the same protocols, were
not (Garcia et al., 1998). Although similar studies have not
been done with the inactivated oil emulsion A/CK/Mexico/
232/94 (H5N2) vaccine, the lack of standardization leaves
such vaccines open to doubt. If vaccine standardization is
improved, there will be lot-to-lot consistency, more cer-
tainty about vaccine efficacy, and the possibility of reduced
vaccine cost, as antigen content can be better defined. An-
other problem in producing an inexpensive vaccine is the
fact that available technologies do not ensure sufficient
antigen content in unconcentrated allantoic fluid. The strat-
egy of reverse genetics now permits the preparation of
high-yield, efficacious virus vaccine for poultry that do not
require concentration or purification.
Neither the commercial H5N2 vaccine nor the standard-
ized reverse genetics H5N3 vaccine provided sterilizing
immunity in chickens; low levels of virus shedding were
detected in birds vaccinated with both types of vaccine.
There is no doubt that H5 influenza vaccines can reduce
clinical symptoms and virus spread, but without standard-
ization of vaccine content, subpotent batches of vaccine will
inevitably occur that may protect against clinical signs of
disease and mask virus shedding. In Hong Kong all vacci-
nated farms have nonvaccinated sentinel birds to guard
against this possibility.
While use of nonstandardized vaccines may not be a
problem for avian influenza disease control, they may be a
serious problem for human pandemic influenza prepared-
ness. Such vaccines have the possibility of masking disease
signs while the birds continue to shed viruses and persis-
tence of virus infection in the presence of a flock immunity
may contribute to increased virus evolution.
Our detection of parental PR8 and rgH5N3 influenza in
mouse brain conflicts with the findings of Subbarao and
colleagues (2003), who did not detect H5N1 made by re-
verse genetics in mouse brain. The viruses differed in their
source of HA and NA, but both viruses derived their re-
maining genes from PR8 (H1N1). Strains of PR8 in differ-
ent laboratories may have point mutations that cause them
to differ in their characteristics. Hatta et al. (2001) showed
that a mutation in PB2 (E627K) plus a cleavable HA is
associated with mouse neurovirulence of the H5N1/97 vi-
ruses. Neither of these features is present in the H5N3 virus;
the PB2 was derived from PR8 (H1N1), and the modified
H5 HA does not possess a series of basic amino acids at the
cleavage site. Because our rgH5N3 viruses are being used as
inactivated preparations, potential neurovirulence presents
no risk to vaccine recipients. On the other hand, these
findings would be of concern if the vaccine were used as a
live, attenuated preparation. Our results highlight the need
to evaluate each influenza virus reassortant carefully, be-
cause our knowledge of neurotropism is incomplete.
The use of an inactivated influenza vaccine containing a
marker NA (N3) permits discrimination between infected
and vaccinated birds. In the present studies, antibodies to
N3 were detected by NI tests, providing the proof-of-prin-
ciple of this strategy. This approach was used previously by
Capua et al. (2002) in the control of H7N1 avian influenza
outbreaks in Italy. It remains to be determined whether
influenza virus vaccines that contain homologous NA or
homologous internal antigens (PB2, PB1, PA, NP, NA, M,
NS) would be more efficacious. The available evidence
indicates that the immunogenicity of HA is the most im-
portant factor in protecting against human infection (Wright
and Webster, 2001), but immunity to NA and to all viral
gene products provides both humoral and cell-mediated
immune responses (Ada and Jones, 1986; Epstein et al.,
1998; Kilbourne et al., 1995). The use of PR8 (H1N1)
internal genes to provide high yields of HA protein and the
use of N3 NA to allow discrimination between infection and
vaccination may have reduced the potential efficacy of the
vaccine, but these “costs” are balanced by the possibility of
providing inexpensive, standardized influenza vaccines that
can discriminate between infections and vaccination of
poultry.
In summary, it has been demonstrated that reverse ge-
netics provides a strategy for preparing high levels of anti-
gen in chicken embryos that can be used to formulate
standardized inexpensive vaccines that are efficacious
against highly pathogenic H5N1 influenza viruses. Such
vaccines may enhance control measures in SE Asia against
continuing reemergence of highly pathogenic H5N1 avian
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influenza viruses in poultry. The potential for these avian
H5N1 viruses to spread to swine and humans is of continu-
ing concern and methods for reducing the level of H5N1
viruses in the field in SE Asia are urgently needed. This will
only be achieved by a combination of improved biosecurity,
effective surveillance, and monitoring plus support from an
effective vaccination program. In addition to providing the
strategy for providing sufficient antigen for standardized
vaccine, reverse genetics permits rapid changing of the
vaccine strain when antigenic drift occurs.
Materials and methods
Viruses
Influenza viruses A/PR/8/34 (H1N1), A/Goose/Hong
Kong/437-4/99 (H5N1), A/Duck/Germany/1215/73 (H2N3),
A/Chicken/Hong Kong/86.3/02 (H5N1), and A/Chicken/
Hidalgo/28159-232/94 (H5N2) were obtained from the repos-
itory of St. Jude Children’s Research Hospital. The highly
pathogenic H5N1 viruses were handled in BL3 facilities at
St. Jude Children’s Research Hospital.
Reverse genetics
RT-PCR was performed with segment-specific primers
as previously described (Hoffmann et al., 2001). Briefly,
RNA was isolated by using the RNeasy kit (Qiagen) and
transcribed to cDNA with the Uni12-primer (AGC AAA
AGC AGG). Plasmids encoding the PB1, PB2, PA, NP, M,
and NS genes of influenza PR8 were constructed as previ-
ously described (Hoffmann et al., 2002) and were desig-
nated pHW191-PB2, pHW192-PB1, pHW193-PA,
pHW195-NP, pHW197-M, and pHW198-NS. The plasmid
pHW251-HA5, which encoded the HA of the A/Goose/
HK/437-4/99 (H5N1) virus with a deletion of the polybasic
amino acid region at the HA1–HA2 cleavage site, was
derived by PCR amplification of two fragments of the plas-
mid pHW250-HA encoding the full-length H5. The primers
used for the amplification of the two fragments have HA-
specific regions (in bold) flanked by sequences for the type
II restriction enzyme BsmBI (underlined):
Bm-HA-1: 5-TATTCGTCTCAGGGAGCAAAA-
GCAGGGG-3
Bm-H5-1025R: 5-ATTACGTCTCTCCTCTTGT-
CTCAATTTGAGGGGTATT-3
Bm-H5-1020: 5-ATTACGTCTCAGAGGACTA-
TTTGGGGCTATAGCAGG-3
Bm-NS-890R: 5-ATATCGTCTCGTATTAGTAG-
AAACAAGGGTGTTTT-3
The fragments were digested with BsmBI and inserted into
pHW2000-BsmBI by a three-fragment ligation reaction.
The N3 NA of influenza A/Duck/Germany/1215/73 was
cloned into the pHW2000 vector by using PCR and the
N3-specific primers previously described (Hoffmann et al.,
2001). The Center for Biotechnology at St. Jude Children’s
Research Hospital determined the sequence of template
DNA by using Rhodamine or dRhodamine dye-terminator
cycle sequencing ready reaction kits with AmpliTaq DNA
polymerase FS (Perkin–Elmer Applied Biosystems, Inc.,
Foster City, CA) and synthetic oligonucleotides. Samples
were separated by electrophoresis and analyzed on PE/ABI
model 373, model 373 Stretch, or model 377 DNA sequenc-
ers.
Generation of recombinant viruses
Recombinant viruses were generated by DNA transfec-
tion as described previously (Hoffmann et al., 2002).
Briefly, 293T and MDCK cells were cocultured (0.2 to 1 
106 cells of each cell line) and used for the transfection
experiments. The cocultured cells were transfected with a
DNA–lipid complex containing 1 g of each plasmid, 18 l
of transit LT1 (Panvera, WI) in a final volume of 1 ml of
OPTIMEM-I (Gibco, NY). Transfection was carried out for
6 h, at which time the DNA–lipid complexes were removed
and replaced with fresh medium. The cells were incubated
for an additional 24 h, and 0.5 g/ml of TPCK-treated
trypsin (Worthington) was added. After 72 h, the supema-
tant was taken from the cells, and 100 l was injected into
10-day-old embryonated chicken eggs. The allantoic fluid
of this first egg passage stock was analyzed by HA assay
and showed a titer of 2048 HA units/50 l. The allantoic
fluid (200 l) was analyzed by RT-PCR, and each viral
segment was partially sequenced to confirm the identity of
the recombinant virus.
Preparation of vaccines
Viruses were propagated in the allantoic cavities of 10-
to 11-day-old embryonated chicken eggs at 35°C for 48 h.
Allantoic fluid was harvested, and virus was inactivated by
adding -propiolactone (BPL) at a ratio of 1:2000 (vol/vol)
and allowing the fluid to remain at room temperature for 4 h
and then remaining at 4°C for 24 h. Inactivation was con-
firmed by the absence of detectable infectivity after two
blind passages of the treated allantoic fluid in embryonated
eggs.
Virus concentration by Amicon ultrafiltration
Inactivated viruses in allantoic fluid were clarified by
centrifugation at 5000 rpm for 15 min. The supernatant
allantoic fluid was concentrated to 1/10 of its original vol-
ume by use of an Amicon concentrator ultrafiltration appa-
ratus.
Virus purification
The concentrated viruses were purified by ultracentrifu-
gation through a 25 and 70% sucrose cushion and then
pelleted at 27,000 rpm at 4°C for 1 h. The pellet was
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resuspended in STE buffer, sonicated for 2 min, and then
centrifuged on a 25 to 70% sucrose continuous gradient
with an SW28 rotor at 24,000 rpm for 2.5 h. Virus bands
were removed by syringe, diluted in STE, and then pelleted
as described above. The pellets were resuspended and son-
icated in appropriate volumes of STE, and sodium azide was
added at 200 ppm final concentration.
Standardization of vaccine
The content of the hemagglutinin protein in the allantoic
fluid, Amicon-concentrated vaccine, and purified vaccine
was standardized by the single radial immunodiffusion tech-
nique as described previously (Wood et al., 1985), using
reagents specifically developed for H5N1/97 HA (Wood et
al., 2001). The inactivated virus preparations, standardized
in terms of micrograms of H5 HA protein, were emulsified
in paraffin oil, which is currently used commercially to
prepare influenza virus vaccines for poultry.
Commercial H5N2 influenza vaccine
A/Chicken/Mexico/232/94 (H5N2), chemically inacti-
vated and emulsified in mineral oil to act as an adjuvant,
was obtained from Intervet.
Biological testing of reverse genetics derived (rg) H5N3
vaccine
Coturnix quail
Adult quail (B&D Game Farm) were inoculated with 0.5
ml of a 1:10 dilution of rg-A/Goose/HK/437-4/99 (HA) 
A/Duck/Germany/1215/73 (N3) with PR8 internal genes
(rgH5N3) via the natural routes (intratracheally, intraocu-
larly, and intranasally). The trachea and cloaca of each bird
were swabbed on days 2, 4, and 6 postinoculation.
Specific pathogen-free (SPF) white leghorn chickens
Five-week-old chickens (Spafas, CT) were infected with
1.0 ml of a 1:10 dilution of the rgH5N3 virus via natural
routes (intratracheal, intraocular, intranasal). Tracheal and
cloacal samples were taken 2, 4, and 6 days postinoculation.
Six-week-old white leghorn broiler chickens (Marshall
Durbin) were intravenously inoculated with 0.2 ml of a 1:10
dilution of rgH5N3. Tracheal and cloacal swabs were taken
3 days postinoculation.
BALB/c mice
Female 8-week-old mice (The Jackson Laboratory, Bar
Harbor, ME) weighing 18–20 g were used for virus patho-
genicity and replication studies. Mice were anesthetized by
inhalation of isolfluorane and inoculated intranasally with
0.1 ml of 10-fold virus dilutions. The mice were weighed
and observed daily for 16 days for signs of disease and
mortality. To determine virus titers in the lungs and brain,
groups of mice were sacrificed on day 3 or 4 and on day 7,
and virus titers in the tissues were determined by EID50 in
10-day-old embryonated chicken eggs.
Ferrets
Male ferrets 12 to 13 weeks old (Triple F Farms, Sayre,
PA) were used to assess virus replication and pathogenicity.
The animals were seronegative to the currently circulating
human influenza A virus strains [A/New Caledonia/2007/99
(H1N1) and A/Panama/20/99 (H3N2)]. Ferrets were anes-
thetized with isofluorane and inoculated intranasally with
5.8, 6.5, or 7.6 EID50 of virus. Rectal temperatures and
observations were made daily for 11–14 days for disease
signs and mortality. On days 3, 5, and 7, ferrets were
sedated with ketamine–HC1 (30 mg/kg), and 0.5 ml of PBS
was inserted into each nostril, expelled onto a petri dish, and
titrated in 10-day-old embryonated chicken eggs. Fourteen
days after inoculation, the ferret sera were tested by HI for
antibodies to the infecting virus.
Studies of commercial H5N2 vaccine
Forty SPF white leghorn chickens (Spafas) were vacci-
nated subcutaneously with a 0.5 ml volume at the base of
the neck at 8 days of age. In the second experiment, 20 of
the vaccinated chickens received booster doses of vaccine 4
weeks after the first vaccination by the same method and
route. Three weeks after vaccination, chickens were moved
to a BSL3 animal housing facility and challenged with 10
CLD50 of A/CK/HK/86.3/02 (H5N1) in 0.3 ml given intra-
nasally. Unvaccinated, uninfected contact chickens were
placed in cages with vaccinated challenged birds 1 day later
to detect transmission of the challenge virus from vacci-
nated birds. In addition, 10 unvaccinated chickens were
infected with 10 CLD50 or 100 CLD50 of A/CK/HK/86.3/02
(H5N1) in 0.3 ml intranasally to serve as controls for the
highly pathogenic virus. Chickens that were vaccinated and
boosted were challenged 3 weeks postboost with 100
CLD50 of A/CK/HK/86.3/02 (H5N1) in 0.3 ml given intra-
nasally. Three unvaccinated, uninfected chickens were
placed in the same cage to serve as direct contact controls.
In the third experiment, four unvaccinated chickens were
inoculated with 100 CLD50 in 0.3 ml given intranasally and
then placed in cages with vaccinated chickens to determine
whether the vaccinated birds were protected from natural
transmission of the highly pathogenic virus.
Blood was obtained from the wing veins of all chickens
prior to challenge and 10 days postchallenge. Tracheal and
cloacal swabs were taken from chickens on days 3 and 7
postchallenge.
Studies of standardized reverse genetics H5N3 vaccine
Experiment 1
Thirty 2-week-old SPF white Leghorn chickens in six
groups were immunized subcutaneously at the base of the
neck with 0.5 ml of three different inactivated rgH5N3
vaccines, as follows: (1) allantoic fluid virus vaccine, (2)
Amicon-concentrated virus vaccine, (3) purified virus vac-
cine in oil emulsion adjuvant, and (4) normal allantoic fluid
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vaccine. Six weeks later, the chickens’ sera were tested by
HI for immunity to H5N1 virus.
Experiment 2
Forty-five 1-week-old SPF white Leghorn chickens in
five groups were vaccinated subcutaneously at the base of
the neck with 0.5 ml of one of three different rgH5N3-
inactivated viruses. Three weeks later, the chickens’ sera
were tested by HI for immunity to A/CK/HK/86.3/02
(H5N1) virus. The protective effects of vaccination were
evaluated by exposure of the nine vaccinated birds in each
group to one chicken that had been intranasally challenged
with 100 CLD50 of A/CK/HK/86.3/02 (H5N1) virus in 300
l. On day 3 and day 7 after challenge, tracheal and cloacal
swab samples were obtained as previously described (Gar-
cia et al., 1998). Clinical signs were observed for 10 days
after challenge.
Experiment 3
Groups of 1-week-old SPF white Leghorn chickens were
immunized by subcutaneous injection at the base of the
neck with 0.5 ml of allantoic fluid containing inactivated
H5N3 viruses in oil emulsion. Three weeks later, the chick-
ens’ sera were tested by H1 for immunity to A/CK/HK/
86.3/02 (H5N1) virus. The efficacy of the vaccine was
evaluated by exposing the vaccinated chickens to birds
lethally challenged intranasally with 100 CLD50 of A/CK/
HK/86.3/02 (H5N1) in 300 l. On day 3 and day 7 after
challenge, tracheal and cloacal samples were obtained; clin-
ical signs were observed for 10 days after challenge.
Serologic tests
Hemagglutination inhibition and neuraminidase inhibi-
tion (NI) assays were performed as previously described
(Webster et al., 2002a).
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